Rapid Pathogen Screening (RPS), a developer of point-of-care diagnostic tests, has received Health Canada approval for its InflammaDry Detector to detect elevated levels of Matrix metalloproteinase-9 (MMP-9) in tear fluid.

MMP-9 is an inflammatory marker seen in patients with Dry Eye disease and its findings and research shows that MMP-9 may be a more sensitive marker than clinical signs when diagnosing Dry Eye.

The Dry Detector requires only a small sample of human tears to detect elevated levels of MMP-9 and provides results in 10 minutes.

RPS president and CMO Robert Sambursky said providing clinicians with an in-office screening test to detect hidden Dry Eye disease will help identify patients that may benefit from perioperative therapy to improve their ocular surface, leading to better surgical and medical patient outcomes.